Trial Profile
A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary) ; Rituximab
- Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results (n=41) presented at the 25th Congress of the European Haematology Association.
- 12 Jun 2020 According to an BeiGene media release, pooled analysis from 4 studies (NCT04170283; NCT03145064; NCT02569476; NCT03520920) were presented at the 25th European Hematology Association (EHA) Virtual Congress.